a-synuclein is an abundant presynaptic protein that is important for regulation of synaptic vesicle trafficking, and whose misfolding plays a key role in Parkinson's disease. While a-synuclein is disordered in solution, it folds into a helical conformation when bound to synaptic vesicles. Stabilization of helical, folded a-synuclein might therefore interfere with a-synuclein-induced neurotoxicity. Here we show that several small molecules, which delay aggregation of a-synuclein in solution, including the Parkinson's disease drug selegiline, fail to interfere with misfolding of vesicle-bound a-synuclein. In contrast, the porphyrin phtalocyanine tetrasulfonate directly binds to vesicle-bound a-synuclein, stabilizes its helical conformation and thereby delays pathogenic misfolding and aggregation. Our study suggests that small-molecule-mediated stabilization of helical vesicle-bound a-synuclein opens new possibilities to target Parkinson's disease and related synucleinopathies.
P
arkinson's disease is the second most common neurodegenerative disease. It is characterized by specific movement disturbances and affects B1% of the population above 60 years 1 . Pathologically, Lewy bodies constitute the hallmark of the disease 2 . Lewy bodies are intraneuronal aggregates formed by misfolded species of the presynaptic protein a-synuclein (aSyn), as well as a multitude of proteins and lipids [3] [4] [5] [6] [7] . So far, only symptomatic treatment is available for Parkinson's disease and related synucleinopathies. Although the normal function of aSyn is still a matter of debate, recent evidence suggests that aSyn is important for regulation of synaptic vesicle trafficking and neurotransmitter release via SNARE-complex interaction 1, [8] [9] [10] .
Under physiological conditions, aSyn is found in equilibrium between a free monomeric species, which samples a large ensemble of dynamic conformations [11] [12] [13] , and a membranebound a-helical structure [14] [15] [16] [17] [18] [19] . aSyn preferentially interacts with acidic phospholipids 20 where it folds into a single continuous helix extending up to approximately residue 100 (refs 21,22) . In line with the membrane-induced folding of aSyn, two antiparallel, surface-bound helices are formed in the presence of detergent micelles 8, 23, 24 . When aSyn is bound to vesicles, the highly aggregation-prone non-amyloid component (NAC) region (residues 61-95), is in an a-helical conformation and acts as a membrane sensor 25 . Since the NAC region is important for initiating aSyn misfolding and forms the core of amyloid fibrils 26 , stabilization of the helical, vesicle-bound conformation of aSyn might interfere with pathogenic aggregation.
Increasing evidence indicates that the most toxic species of aSyn are soluble oligomeric aggregation intermediates 10, [27] [28] [29] . The search for small chemical compounds that interfere with the aggregation of unfolded, monomeric aSyn into toxic oligomers and fibrils has therefore been intensively pursued using a wide array of in vitro and cellular systems as well as animal models of Parkinson's disease [30] [31] [32] [33] [34] [35] [36] [37] . In contrast, little is known about inhibition of aSyn aggregation in the physiological environment of a vesicle. Indeed, interaction with membranes does not inhibit the potentially pathological process of aSyn aggregation, but can even promote it 20, 38 . Moreover, perturbation of the membrane integrity by aSyn, potentially resulting in formation of membrane pores, was suggested to cause neuronal death 39 .
Here we demonstrate that several small molecules that were previously shown to delay aggregation of soluble, disordered aSyn, are not able to inhibit aggregation of vesicle-bound aSyn. In contrast, the polyphenol phtalocyanine tetrasulfonate (PcTS) directly binds to vesicle-bound aSyn, stabilizes its helical conformation and inhibits misfolding and aggregation. We further show that PcTS prevents inclusion formation and toxicity in a cell model of aSyn aggregation. Thus, our study opens novel possibilities for interfering with aSyn misfolding and neurotoxicity in its physiological environment.
Results
PcTS stabilizes the helical structure of lipid-bound aSyn. A multitude of organic compounds from different chemical classes were shown to modulate aggregation of aSyn in solution [30] [31] [32] [33] 40 . This includes the polyphenols curcumin, baicalein and epigallocatechin gallate (EGCG), the drug selegiline, which is used for treatment of early-stage Parkinson's disease, and the porphyrin PcTS (Fig. 1a ). In agreement with previous studies, curcumin, baicalein and EGCG inhibited almost completely the formation of aSyn fibrils in solution when used at a 15:1 compound-to-protein ratio ( Supplementary Fig. 1 ). Selegiline and PcTS reduced ThT staining to a smaller degree ( Supplementary  Fig. 1 ). PcTS was previously shown to favour prefibrillar aSyn species 34 .
Next, we tested whether curcumin, selegiline, baicalein, PcTS and EGCG interfere with the binding and folding of aSyn on the surface of small unilamellar vesicles (SUVs) 21 . To address this question, we formed SUVs from a 1:1 mixture of 1-palmitoyl-2-oleoyl phosphatidylcholine (POPC) and 1-palmitoyl-2-oleoyl phosphatidic acid (POPA). NMR spectroscopy showed that selegiline, baicalein and EGCG interact with POPA/POPC liposomes ( Supplementary Fig. 2 ). Nevertheless, none of the compounds impaired vesicle binding of aSyn and its folding into an a-helical conformation even at a 15-fold excess of compound with respect to aSyn (Fig. 1b and Supplementary Fig. 3 ).
Are the small molecules able to modulate the aggregation of aSyn in the presence of vesicles? To address this question, aSyn was subjected to aggregation-promoting conditions (37°C, constant stirring) for 10 days in the absence and presence of the small molecules. When no compound was present, the a-helical content of aSyn decreased from B70% to below 25% (Fig. 1b-d) . In parallel, b-structure was formed, the sample stained for the amlyoid-dye thioflavin T (ThT) and electron microscopy revealed fibrillar structures (Fig. 1c,e ,f,i), consistent with previous results 1, 34, 41 . Despite its strong antiaggregation capacity towards soluble aSyn ( Supplementary Fig. 1 ), curcumin did not block the transition from a-helix to b-structure of vesiclebound aSyn nor the formation of amyloid fibrils (Fig. 1c-f and Supplementary Fig. 4 ). Selegiline, baicalein and EGCG also did not interfere with the loss of a-helical structure (Fig. 1c,d ), although samples aggregated in the presence of EGCG and baicalein stained only weakly for ThT, probably as a result of competition with the compounds for binding sites on aSyn fibrils (Fig. 1f) . The amount of fibrils observed in EM micrographs in the presence of EGCG was small ( Supplementary Fig. 4 ), indicating that EGCG directs aSyn into off-pathway aggregates both in solution 32 and in the presence of vesicles. Curcumin, baicalein, selegiline and EGCG were used at a 15:1 compound-toprotein ratio. The reported apparent binding constants of curcumin and baicalein to aSyn are 10 mM and 500 nM, respectively, while selegiline does at best bind weakly to monomeric aSyn, but interacts with oligomeric species 30, 31, 33, 42, 43 .
In contrast to curcumin, selegiline, baicalein and EGCG, no ThT signal was detected after 10 days of incubation of vesiclebound aSyn when PcTS was present (Fig. 1f) . In addition, EM micrographs were free of fibrillar structures and the vesicle morphology appeared unmodified (Fig. 1h,j) . Quantification of the secondary structure indicated that even after 10 days of incubation in aggregation-prone conditions the a-helix content remained at B41% and less than 10% of b-structure was formed (Fig. 1c-e) . Thus, PcTS is able to stabilize the helical, membranebound conformation of aSyn and inhibit its aggregation in the presence of vesicles. PcTS also inhibited aSyn aggregation in the presence of large unilamellar vesicles (LUVs; Fig. 2 ). Experiments at different aSyn:compound ratios further showed that a 5:1 but not a 1:1 PcTS:aSyn ratio was sufficient to inhibit amyloid formation ( Supplementary Fig. 5 ).
PcTS releases the NAC region from the vesicle surface. To obtain insight into the mechanism of the stabilization of the ahelical structure of membrane-bound aSyn by PcTS, we used solution NMR spectroscopy. Although the slow tumbling rate of vesicles induces lipid-bound aSyn to exhibit dynamic properties that hamper its direct observation by solution NMR, exchange with the NMR-visible, lipid-free form allows residue-specific access to the properties of the membrane-bound state 24 . We probed this exchange process using two-dimensional 15 The lipid-to-protein molar ratio was 125:1. In the presence of PcTS, the a-helix content was B41% and less than 10% of b-structure was formed after 10 days of incubation in aggregation-prone conditions. (d-f) a-helix (d) and b-sheet (e) content together with ThT fluorescence (f) aggregation kinetics of vesicle-bound aSyn. The control did not contain any small molecule. Error bars represent ± s.d. from the mean of at least three different experiments. As the C-terminal domain remains disordered in vesicle-bound aSyn 13 , the maximum a-helical content is B70%. In wt aSyn fibrils, the central domain (approximately residues 38-96 with some loops) is converted into b-structure 60 , corresponding to a b-structure content of B40%. (g-j) Electron micrographs of fresh (g,h) and aggregated (i,j) aSyn/SUV samples: control (g,i) and PcTS (h,j). The white bar represents 500 nm. NATURE COMMUNICATIONS | DOI: 10.1038/ncomms6857 ARTICLE lipid ratio). In line with previous studies 24 , the NMR signal intensities of the 100 N-terminal residues were strongly decreased compared with free aSyn ( Fig. 3a red spectrum; 3b, red line). The observed signal originates from unbound aSyn, as the bound protein does not contribute 24 . In the C-terminal region, the NMR resonances had a comparable intensity as in the free state, indicating that they interact at best weakly with vesicles.
Upon addition of 1.5 mM PcTS (15:1 compound-to-protein ratio), the cross-peaks of residues in proximity to Y39 and F94 as well as at the N terminus were further attenuated and shifted (Fig. 3a-c and Supplementary Fig. 6 ). The intensity decrease and chemical shift changes are caused by the binding process and were previously observed upon addition of PcTS to soluble aSyn 34 . It shows that PcTS is in solution and can bind to the residual unbound protein. In contrast, residues within the NAC region (residues 61-95) gained B20-30% of intensity (Fig. 3a , black spectrum; Fig. 3b, black bars; Fig. 3c ). In addition, at higher lipid-to-protein ratios, when no NMR signals are observed for the N-terminal 100 residues, addition of PcTS led to the appearance of resonances from the NAC region ( Supplementary Fig. 7 ). Thus, PcTS promotes a faster exchange of the NAC region between the vesicle-bound and free state, making NAC residues 'visible' in the NMR spectrum. Using a different buffer system (50 mM phosphate, pH 7.4) and/or different liposome composition (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS) and 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) in a 5:3:2 ratio) yields the same behaviour in which the NAC region of aSyn is released from its interaction with the membrane (Fig. 4) . In addition, the concentrations of PcTS used here are not sufficiently large to interfere with the formation of liposomes ( Supplementary Fig. 8 ). In contrast to PcTS, addition of curcumin, selegiline and baicalein did not change the NMR signal intensity profile of aSyn in the presence of POPC/POPA vesicles (Fig. 5) . EGCG further reduced the NMR signal intensity of residues 1-130, consistent with the EGCG-mediated conversion of aSyn molecules, which are not bound to the vesicles, into off-pathway oligomeric species.
Interaction with Y39 and F94 drives NAC-domain release. It was previously shown that PcTS directly binds to monomeric, soluble aSyn 34 . The interaction is driven by aromatic stacking with F4, Y39 and F94. In order to study the importance of Y39 and F94 for binding of PcTS to membrane-bound aSyn, we generated the aSyn mutants Y39A and F94A, as well as the double mutant Y39A/F94A. The SUV-induced intensity profiles of the mutants were similar to that of wild-type (wt) aSyn (Fig. 6a-c) , indicating a similar affinity and mechanism of membrane binding. This was confirmed by determination of a dissociation constant of B60 ± 15 mM in all cases (assuming a one-site binding model; Fig. 5a ). It also suggests that Y39 and F94 are not important for anchoring aSyn to POPA/POPC vesicles, consistent with the observation that Y39 is primarily waterexposed when aSyn is bound to vesicles 44 . We then added PcTS to the aSyn variants in complex with vesicles. In the presence of a 15-fold excess of PcTS, NMR signal intensities in the NAC region of the Y39A mutant increased by B15% (Fig. 6a) , while the wt protein regained B20-30% (Fig. 3b,c) . In case of the F94A variant of aSyn, the PcTSinduced signal increase remained also below that of wt aSyn and was only slightly larger than for the Y39A mutant (Fig. 6b) . Notably, simultaneous mutation of Y39 and F94 abolished the PcTS-induced signal increase in the NAC region (Fig. 6c) . Thus, the partial release of aSyn's NAC residues from the membrane surface is specifically because of the interaction of PcTS with Y39 and F94.
To obtain further insight into the aSyn-membrane interaction, we performed 15 N spin relaxation measurements. Previous experiments had shown that the exchange with the membranebound a-helical state enhances the relaxation of the NMR resonances of disordered soluble aSyn 24, 45 . Consistent with this finding, addition of SUVs increased the transverse 15 N spin relaxation rate from B3 to 14 s À 1 for residues 1-40 and to B12 s À 1 for residues 40-100 (Fig. 6d) . In the presence of PcTS, relaxation rates in the N-terminal part of wt aSyn remained high, while in the NAC region the average 15 N transverse relaxation rate decreased from B12 to 7 s À 1 (Fig. 6d,e) . The decreased contribution of the vesicle-bound state to the observed spin relaxation rate supports a PcTS-induced partial release of the NAC region of wt aSyn from the vesicle surface. In contrast, no PcTS-induced changes in relaxation rates were observed for the Y39A/F94A variant of aSyn (Fig. 6e,f) , in agreement with the importance of Y39 and F94 for PcTS binding and NAC domain release.
A distinct aggregation pathway of vesicle-bound aSyn. Next, we asked whether the PcTS-mediated inhibition of aggregation of vesicle-bound aSyn (Fig. 1) is connected to the PcTS-induced partial release of aSyn's NAC region from the membrane surface (Figs 3 and 6). To address this question, we analysed the influence of PcTS on the aggregation of both wt and mutant aSyn in the presence of vesicles (Fig. 7) . While PcTS completely blocked aggregation of vesicle-bound wt aSyn, the aSyn variants were able to form amyloid fibrils in the presence of PcTS (Figs 1 and 7) . Aggregation of the Y39A/F94A double mutant in the presence of PcTS even approached the aggregation behavior of wt aSyn in the absence of PcTS (Fig. 7) , despite the fact that its vesicle-induced broadening profile did not differ from that of wt aSyn (Fig. 6c) . The slower fibrillization rate of the single point mutants when compared with Y39A/F94A aSyn (Fig. 7a ) is in agreement with a PcTS-induced partial release of the NAC region of Y39A aSyn and F94A aSyn from the vesicle surface (Fig. 6a,b ). The data demonstrate that membrane attachment of the NAC region is essential for aggregation of aSyn in a lipid environment.
It was previously shown that Y39 is important for aSyn aggregation in solution. When Y39 was mutated to alanine, the ARTICLE formation of fibrils was strongly delayed (Fig. 8) 34 . Given the differences at the microenvironmental level between free and vesicle-bound aSyn, we asked whether the presence of this aromatic residue at position 39 plays a similar role for vesiclebound aSyn. However, the Y39A mutation did not interfere with the aggregation of vesicle-bound aSyn (Fig. 8) . The distinct aggregation behaviour of the Y39A variant of aSyn in solution and when bound to vesicles demonstrates that the early stages of aggregation differ drastically between the free, disordered and the membrane-bound a-helical aSyn.
PcTS reduces aSyn inclusion formation and cytotoxicity. In order to determine the effect of PcTS on aSyn aggregation and aSyn-induced cytotoxicity, we employed a previously described cell model 46 that leads to protein inclusion formation positive for aSyn. Addition of 0.1 and 1 mM of PcTS to H4 cells expressing aSyn did not modify inclusion formation. In contrast, treatment with 10 mM PcTS for 48 h decreased the percentage of cells with inclusion formation (Fig. 9a,b ). Next, we tested whether PcTS would also influence aSyninduced cytotoxicity in the same cell model. Toxicity was determined 48 h after transfection and start of PcTS treatment by determining the release of lactate dehydrogenase into the medium. We determined no effect on aSyn toxicity in the vehicle control, but observed a drop in LDH release upon treatment with 10 mM PcTS, the same concentration that led to inclusion modulation (Fig. 9c) .
Discussion aSyn is important for regulation of synaptic vesicle trafficking 8 and is found in both soluble and membrane fractions of neuronal cells 9, 16 . Consistent with a physiological role of the membranebound conformation of aSyn, its N-terminal 100 residues have a high propensity to bind to negatively charged vesicles and fold into an a-helical conformation 25, 47 . At the same time, aSyn can misfold, aggregate and form fibrils when it is in contact with phospholipid vesicles 38 pointing also to a pathological role of membrane-bound aSyn.
Aggregation of vesicle-bound aSyn, which has a low surface coverage when compared with other peripheral membrane proteins such as apocytochrome c 44 , was suggested to occur through a two-state process 48 . Initially, the N terminus and the ARTICLE conformation and formation of elements of b-structure 48 . A further step during aggregation of vesicle-bound aSyn is oligomerization through the NAC domain, which occurs either parallel to the unfolding of the helical conformation or subsequent to it 48 , followed by formation of amyloid fibrils. Amyloid fibrils formed in the presence of POPC/POPA vesicles closely resembled those formed in the absence of lipid vesicles and were immersed in a network of vesicles with substantially perturbed morphology 48 . A direct attachment of fibrils to SUVs is also supported by studies on the islet amyloid polypeptide, which showed that its fibrils line the surface of distorted phospholipid vesicles, in agreement with the notion that fibril growth at the membrane and membrane damage are physically connected 49 . Our data support the above aggregation model and reveal a way to interfere with aggregation of aSyn in contact with synaptic vesicles. PcTS directly binds to Y39 and F94 of membrane-bound aSyn. This interaction partially releases the NAC domain from the membrane surface (Figs 3 and 6 ) such that the helical conformation in the NAC region is less prone to membraneassisted unfolding, subsequent oligomerization and amyloid formation (Figs 1, 7 and 10) .
Inhibition of aSyn aggregation in the membrane-bound state is specific to PcTS, since several other small molecules, which inhibit aggregation of aSyn in solution, did not stop aggregation in the lipid environment (Fig. 10) . This suggests that compounds such as curcumin and baicalein primarily act at the stage of soluble oligomer formation, while their affinity to monomeric aSyn is low. In addition, baicalein, selegiline and EGCG interact with liposomes ( Supplementary Fig. 2 ), further decreasing their efficacy in a lipid environment. PcTS, on the other hand, does not bind to liposomes and readily interacts with monomeric aSyn both in the absence and presence of lipid membranes. The green tea polyphenol EGCG also attenuated the formation of b-sheetrich amyloid fibrils in the presence of vesicles, in agreement with its ability to bind to monomeric polypeptides 32 . However, in contrast to PcTS, EGCG was not able to stabilize the helical, membrane-bound conformation of aSyn (Fig. 1) . Instead, it directs aSyn into heterogeneous off-pathway oligomers 32 . It has also been demonstrated that, while EGCG is able to prevent the formation of aggregates and to disrupt already formed fibrils of the islet amyloid polypeptide when used in solution, its ability to do so in a phospholipid interface is greatly diminished 50 . Whether this is the result of a less accessible protein interface for the compound, membrane binding of EGCG or stabilization of the fibril by its interaction with phospholipids is unknown. The effectiveness of small molecules to inhibit aggregation of vesiclebound proteins might also be related to changes in the aggregation pathway of the protein in the presence of lipids. Whatever the case, the combined data suggest that compounds, which show strong antiaggregation properties in solution, do not necessarily have the same efficacy when used in the presence of lipids. Thus, it is important to assess the antiaggregation properties of small molecules in a lipid environment, in particular as disruption of the cellular membrane might be a key mechanism how fibrillar/oligomeric species of aSyn acquire their neurotoxic properties.
The fact that Y39 is essential for aggregation of aSyn in solution 34 but not when bound to membranes (Fig. 8) shows that the very first stages of aggregation in a membrane environment are different from those that happen in solution. In solution the lack of an aromatic side chain in position 39 would interfere with the self-assembly process of aggregation, whereas in a membrane environment aggregation initially depends on the insertion of hydrophobic residues within the NAC domain and does not need aromatic residues for pathogenic aggregation 47 . PcTS inhibits the aggregation of prion proteins and has been investigated for its in vivo prophylactic and therapeutic effects in scrapie disease 42 . Inhibition of protease-resistant prion aggregates is achieved through stabilization of the native globular structure of the prion protein 51 . Thus, PcTS is able to stabilize well-folded protein conformations both in solution (prion protein) and on the membrane surface (aSyn; Fig. 1 ). PcTS is also likely to interfere with aggregation of membrane-bound b-synuclein, which has recently been shown to aggregate and cause neuronal loss in the rat brain 52 . b-synuclein binds membranes similar to aSyn and both Y39 and F94 are conserved 53 .
Given the wide variety of models that have been proposed to explain the misfolding and aggregation of aSyn, the role of membrane interaction has generated mixed viewpoints. These range from the complete stabilization of the 'native state' of aSyn and inhibition of aggregation upon binding of aSyn to vesicles 9, 16, 17, 54 to the formation of damaging pore-like oligomers formed only in the presence of membranes 39 . As part of these complex processes, aSyn maintains an equilibrium between a free and membrane-bound state and-under stress conditions-is prone to form soluble oligomers and fibrils. However, our study suggests that the mechanism by which aSyn aggregates is very different when it is bound to vesicles than when it is free in solution. We also demonstrate that the detachment of the NAC domain of aSyn from the vesicle surface greatly delays its aggregation and, to the best of our knowledge, this is a unique effect of PcTS. The importance of membrane attachment of the NAC domain for aSyn aggregation is consistent with a recent study, which showed that the NAC domain acts as a sensor of lipid properties and determines the affinity of aSyn membrane binding 25 . Because the antiaggregation effect of PcTS is much stronger for vesicle-bound aSyn than soluble, disordered aSyn, it is likely that PcTS reduces aSyn inclusion formation and cytotoxicity through binding to membrane-attached aSyn. Our study therefore suggests that small molecule-mediated stabilization of the helical membrane-bound state of aSyn provides unique opportunities for inhibiting misfolding and pathogenic aggregation of aSyn in the physiological environment of a synaptic vesicle. Detailed knowledge about the structural basis of aSyn aggregation, together with a screening procedure for small molecules that is targeted to helical vesicle-bound aSyn, promises new ways to approach Parkinson's disease and related synucleinopathies.
Methods
Expression and purification of aSyn variants. pT7-7 plasmid encoding for human wt aSyn was kindly provided by the Lansbury Laboratory, Harvard Medical School, Cambridge, MA. A codon replacement was performed for residue Y136 (TAC to TAT) to avoid codon usage problems 55 . The resulting construct was then used as the template for mutagenesis reactions. Mutations were performed by using the QuikChange II site-directed mutagenesis kit (Stratagene) and verified by DNA sequencing. Plasmids containing aSyn variants were expressed in Escherichia coli BL21 (DE3) cells. Protein expression and purification was performed as previously described 56 . For production of 15 N-labelled proteins, M9-minimal medium supplemented with 15 NH 4 Cl (Cambridge Isotope Laboratories) was used.
Preparation of unilamellar vesicles. POPC and POPA, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS) and 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) were obtained from Avanti Polar Lipids. For vesicle formation, a 1:1 ratio of POPC:POPA or a 5:3:2 ratio of DOPE:DOPS:DOPC was dissolved in a 4-ml mixture of chloroform/ methanol (1:1 vol/vol), followed by evaporation of all solvents under a stream of N 2 gas and lyophilized overnight. The resulting lipid film was hydrated in 50 mM HEPES, 100 mM NaCl, pH 7.4 or in 50 mM Na-phosphate buffer (pH 7.4), 100 mM NaCl to obtain a total lipid concentration of 12.5 mM. For preparation of SUVs, the suspension was sonicated at 37 kHz (four times for 10 min with 5 min breaks at room temperature or until the sample was transparent) in a glass tube. SUVs were isolated using ultracentrifugation at 55,000 r.p.m. in a Beckman TLA 100.3 rotor for 2 h at 298 K. The isolated SUVs had a hydrodynamic diameter of 35 ± 10 nm according to dynamic light scattering. LUVs were prepared following the same procedure but with only two rounds of sonication and no ultracentrifugation step. Dynamic light scattering estimated the hydrodynamic diameter of the LUVs as 105 ± 25 nm.
Aggregation of vesicle-bound aSyn. PcTS was purchased from MP Biomedicals (MP Biomedicals S.A., Heidelberg, Germany). Selegiline, curcumin, baicalein and EGCG were purchased from Sigma (Sigma-Aldrich Chemie GmbH, Schnelldorf, Germany).
SUVs and LUVs were mixed with purified aSyn variants at a 125:1 molar ratio of phospholipid to protein in 50 mM HEPES, 100 mM NaCl pH 7.4, 0.02% sodium azide (with final concentrations of 12.5 mM of phospholipids and 100 mM for aSyn). All compounds were solubilized in a 500 mM stock solution of dimethyl ARTICLE sulfoxide and added to the working solution for final concentrations of 0.1, 0.5 and 1.5 mM (giving 1:1, 5:1 and 15:1 compound to protein ratios). Subsequently, samples were subjected to aggregation-prone conditions (37°C B300 r.p.m.) in low binding protein 1.5 ml Eppendorf tubes over a period of 10 days. After different incubation times, a 20-ml aliquot of the sample was mixed with 1 ml of a 100 mM ThT solution. Fluorescence emission was measured between 460 and 600 nm on a Varian Cary Eclipse fluorescence spectrophotometer (Agilent Technologies) with excitation wavelength of 442 nm at 20°C. The averaged data points were fitted to a sigmoidal equation (data are presented as mean±s.e., n ¼ 3).
CD spectroscopy. Far UV-CD measurements were performed at 20°C on a Chirascan (Applied Photophysics, UK) circular dichroism spectrometer, using a protein concentration of 10 mM in a quartz cuvette with 0.1-cm light path. For vesicle-bound aSyn, SUVs or LUVs were added to a final concentration of 1.5 mM. Each experiment was repeated at least twice. Baseline correction was performed with the same buffer. Data were expressed as the mean residue ellipticity (degree cm 2 d mol -1 ). Estimation of secondary structure content was performed by neuralnetwork analysis using the programme K2D available at the DichroWeb server 57 .
NMR spectroscopy. NMR samples contained 0.1 mM 15 N-labelled wt or mutant aSyn in 50 mM HEPES buffer, 100 mM NaCl, pH 7.4 or 50 mM Na-phosphate buffer, 100 mM NaCl at pH 7.4 and 90% H 2 O/10% D 2 O. NMR experiments were recorded on a Bruker Avance 600 MHz spectrometer. The temperature was set to 15°C. Data processing was performed using the software packages Topspin (Bruker) and CCPN Analysis 58 .
To probe the binding of aSyn variants to vesicles, 2D 15 N-1 H HSQC spectra were recorded in the presence of either 12.5 mM SUV or LUVs. The same stock solution of compounds in DMSO was used for the NMR experiments in the same ratios; therefore, the final DMSO concentration never surpassed 1% of the total volume. 15 Transmission electron microscopy. A solution containing protein was applied to glow-discharged carbon-coated grids and stained with 1% uranyl acetate. Images were taken in a Philips CM120 electron microscope (Philips Inc.) at a defocus of 2.3 mm using a TemCam 224 A slow scan CCD camera (TVIPS, Gauting, Germany).
Cell culture and transfection. H4 neuroglioma cells were maintained at 5% CO 2 and 37°C in Optimem medium (Gibco) supplemented with 10% fetal calf serum and 1% Penicillin Streptomycin. One day before transfection cells were seeded in 24-well plates. Cells were transiently transfected with aSyn using Metafectene (Biontex) according to the manufacturer's instructions. PcTS compound in DMSO was added in concentrations of 100 nM, 1 mM and 10 mM to the cells. aSynexpressing cells were treated with DMSO to exclude vehicle effects.
Immunocytochemistry. Cells were fixed with 4% paraformaldehyde in PBS 48 h after transfection and start of PcTS treatment. For permeabilization cells were subsequently treated with 0.1% Triton X-100 and blocked with 1.5% bovine serum albumin (BSA) in PBS. Cells were then incubated with anti-aSyn antibody (BD 610787, 1:2,000) either 4 h at room temperature or overnight at 4°C and 3 h in Alexa Fluor donkey anti-mouse 555 (Invitrogen A31570, 1:2,000). Cells were further stained with Hoechst (Molecular Probes 33258) for 5-10 min. Images were captured using a Leica DMI 6000B.
LDH activity. LDH activity was measured via release of LDH into the culture medium with the Cytotoxicity Detection Kit (LDH; Roche). Basic LDH release was measured in non-transfected cells, total LDH release was measured by cell lysis in 2% Triton X-100. Absorbance was measured with the Infinite M200 PRO (Tecan) plate reader at 490 nm. Experimental values were calculated in percentages of total LDH release and normalized to tranfection with SynT without treatment. Statistical analysis was conducted using GraphPad Prism 4.03 and included paired, two-tailed Student's t-test.
